Pddr Medical Products & Services (I) Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 03-07-2024
- Paid Up Capital ₹ 0.10 M
as on 03-07-2024
- Company Age 8 Year, 1 Month
- Last Filing with ROC 31 Mar 2019
- Open Charges ₹ 17.00 M
as on 03-07-2024
- Revenue 32.34%
(FY 2019)
- Profit -21.75%
(FY 2019)
- Ebitda -51.81%
(FY 2019)
- Net Worth -122.45%
(FY 2019)
- Total Assets -15.98%
(FY 2019)
About Pddr Medical Products & Services (I)
The Company is engaged in the Business Services Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2019. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹1.70 Cr.
Sunil Ghurde and Dhananjay Jawanjal serve as directors at the Company.
- CIN/LLPIN
U74999MH2016PTC286620
- Company No.
286620
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
06 Oct 2016
- Date of AGM
30 Sep 2019
- Date of Balance Sheet
31 Mar 2019
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Nagpur, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Pddr Medical Products & Services (I)?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Sunil Ghurde | Additional Director | 23-Mar-2024 | Current |
Dhananjay Jawanjal  | Director | 06-Oct-2016 | Current |
Financial Performance and Corporate Structure Insights of Pddr Medical Products & Services (I).
Pddr Medical Products & Services (I) Private Limited, for the financial year ended 2019, experienced significant growth in revenue, with a 32.34% increase. The company also saw a substantial fall in profitability, with a 21.75% decrease in profit. The company's net worth observed a substantial decline by a decrease of 122.45%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Pddr Medical Products & Services (I)?
In 2019, Pddr Medical Products & Services (I) had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Jeevannatural Science Multi Services India Private Limited
Active 5 years 4 monthsDhananjay Jawanjal is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 09 May 2017 | ₹1.70 Cr | Open |
How Many Employees Work at Pddr Medical Products & Services (I)?
Unlock and access historical data on people associated with Pddr Medical Products & Services (I), such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Pddr Medical Products & Services (I), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Pddr Medical Products & Services (I)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
